ReviewIndian journal of ophthalmology2026
The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-vascular endothelial growth factor (anti-VEGF) therapy is the mainstay of management for diabetic macular edema (DME), but marked variability in response, high injection frequency, and cumulative treatment burden highlight the need for tools that can individualize treatment beyond protocol-driven regimens. Artificial intelligence (AI) offers a pathway toward more individualized risk stratification and prognostic support primarily by capturing statistical associations rather than biological mechanisms. Deep learning systems have achieved great accuracy in detecting diabetic retinopathy (DR) and DME. Several autonomous DR/DME screening solutions are in clinical use. Recent advances have applied supervised machine learning, convolutional neural networks, generative adversarial networks, and ensemble methods to multimodal data from fundus images, baseline and follow-up optical coherence tomography (OCT), along with clinical and biochemical data, to classify likely responders and non-responders. These models automatically quantify and track imaging biomarkers to accurately predict central subfield thickness and vision outcomes after loading doses, and estimate future injection burden. AI-driven decision-support tools analyze vast amounts of patient data, treatment histories, and integrate multimodal data, including fundus images, OCT images, and systemic data to provide recommendations for optimal treatment and follow-up, tailored to each individual profile. The AI systems can potentially generate individualized risk and response profiles that can support decisions on initiating therapy, choosing between agents, tailoring treat-and-extend intervals, and timing switches to steroids or combination strategies. However, issues of generalizability, transparency, workflow integration, and ethical deployment need to be systematically addressed. AI-enabled decision support for patient selection and treatment response prediction is poised to become an integral component of anti-VEGF therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.